Last reviewed · How we verify
NCT06368908: FMS_ICU
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill
NA trial testing Transcutaneous Functional Magnetic Muscle Stimulation in Critical Illness Myopathy in 20 participants. Currently enrolling.
30 October 2024
Quick facts
| Lead sponsor | General and Teaching Hospital Celje |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 8 December 2023 |
| Primary completion | 30 October 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across Slovenia |
Drugs / interventions tested
- Transcutaneous Functional Magnetic Muscle Stimulation
Conditions studied
- Critical Illness Myopathy — all drugs for Critical Illness Myopathy →
Sponsor
General and Teaching Hospital Celje
Who can join
Adults 18 to 100, any sex, with Critical Illness Myopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ICU-Acquired weakness (ICU-AW) is a significant complication of critical illness. ICU-AW is common in patients with sepsis, systemic inflammatory response, and mechanically ventilated. It is estimated that around 50% of patients recovering from the primary illness remain in intensive care with characteristic muscle weakness. This leads to dependence on mechanical ventilation, prolonging costly intensive care hospitalization. The myopathy causes persistent functional impairment, endangering patients long after hospital discharge. Magnetic stimulation prevents inactivation atrophy of skeletal muscles, as demonstrated in the mobilized limb of rats. Transcutaneous magnetic stimulation of the quadriceps via the femoral nerve is a safe and painless method even when applied to humans. In patients with chronic obstructive pulmonary disease (COPD), quadriceps magnetic stimulation increased spontaneous contraction force compared to the control group and improved quality of life. Patients with COPD tolerate quadriceps magnetic stimulation well, as it does not affect oxidative stress in muscles but does increase the size of slow-twitch muscle fibers. In intensive care medicine, magnetic stimulation has been primarily used for diagnostic purposes in assessing diaphragm function, peripheral muscle strength assessment, and transcranial electrical stimulation as a diagnostic tool and therapeutic stimulation of brain cells. With the development of modern transcutaneous magnetic stimulators, the possibility arises for their use in intensive care medicine for therapeutic purposes such as preventing critical illness myopathy. To date, no research has been conducted on the use and effectiveness of magnetic stimulation of peripheral muscles in critically ill individuals. The aim of the study is to investigate the effect of Functional Muscle Magnetic Stimulation (FMS) on the development of ICU-AW.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Functional Magnetic Neuromuscular Stimulation vs. Routine Physiotherapy in the Critically Ill for Prevention of ICU Acquired Muscle Loss: A Randomised Controlled Trial.
Skočir A, Jevšnik A, Plaskan L, Podbregar M. · · 2024 · cited 3× · PMID 39459511 · DOI 10.3390/medicina60101724
Verify or expand the search:
- PubMed search for NCT06368908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critical Illness Myopathy
Currently open trials in the same condition.
- NCT07478367 — Critical Illness Weakness Outside the Intensive Care Unit. · recruiting
- NCT03810768 — Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness · recruiting
- NCT03753412 — Recovery From ICUAW Following Severe Respiratory and Cardiac Failure · recruiting
Other General and Teaching Hospital Celje trials
Trials by the same sponsor.
- NCT05857085 — Novel Therapeutics and Endothelial Dysfunction in T1DM Patients · Phase 4 · completed
- NCT06360770 — Assessement of Microcirculation With NIRS Predicts Sepsis Development in Patients With Severe Covid-19 Pneumonia · completed
- NCT04355026 — Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06368908 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General and Teaching Hospital Celje
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06368908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing